Showing 221-230 of 325 grants

Title Institution Researcher Program Duration Total Award Amount
Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D Massachusetts General Hospital Mark Poznansky Cures 01-April-2023 to 31-March-2026 $777.168,00
The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation. Rutgers Biomedical and Health Sciences Derek Sant’Angelo Cures 01-March-2023 to 28-February-2027 $552.029,35
Modulate beta cell proliferation and immunogenicity via aptamer-decorated lipid nanoparticles University of Miami Paolo Serafini Cures 01-April-2023 to 31-March-2026 $894.602,00
Multicolor cellular immunoimaging of response to transplanted islet cells Michigan State University Bryan Smith Cures 01-June-2023 to 31-May-2026 $750.000,00
Spotlight-AQ 2 Center RCT Children's Mercy Hospital Cintya Schweisberger Improving Lives 01-September-2023 to 31-August-2026 $710.434,16
A Cure for Type 1 Diabetes University of Massachusetts Medical School David Harlan Cures 01-October-2022 to 30-September-2025 $12.998.645,40
JDRF-IQVIA Adult T1D Detection IQVIA, Inc. Nadejda Leavitt Cures 01-October-2022 to 31-August-2025 $953.780,00
Enabling studies to advance intra-lymph node depots as a durable antigen-specific immunotherapy for T1D University of Maryland Christopher Jewell Cures 01-February-2023 to 31-January-2026 $989.997,00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-March-2026 $897.822,00
Type 1 Diabetes Consortium – New Onset Workstream Critical Path Institute (C-Path) Joseph Hedrick Cures 28-October-2022 to 31-December-2025 $1.132.723,00